IDYA Ideaya Biosciences

IDEAYA Biosciences Inc. is a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality - which represents an emerging class of precision medicine targets.

IDYA stock data


Investment data

Data from SEC filings
Securities sold
Number of investors


10 Aug 21
28 Oct 21
31 Dec 21
Quarter (USD)
Jun 21 Mar 21 Dec 20 Sep 20
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 90.53M 90.53M 90.53M 90.53M 90.53M 90.53M
Cash burn (monthly) 15.44M 4.76M 3.68M 2.54M 4.31M (positive/no burn)
Cash used (since last report) 61.09M 18.83M 14.57M 10.04M 17.05M n/a
Cash remaining 29.44M 71.7M 75.96M 80.49M 73.48M n/a
Runway (months of cash) 1.9 15.1 20.6 31.7 17.0 n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
25 Oct 21 Michael Anthony White Stock Option Common Stock Grant Acquire A No No 22.01 200,000 4.4M 200,000
4 Oct 21 Michael P. Dillon Common Stock Sell Dispose S No Yes 26.621 1,000 26.62K 78,789
4 Oct 21 Michael P. Dillon Common Stock Sell Dispose S No Yes 25.848 500 12.92K 79,789
4 Oct 21 Michael P. Dillon Common Stock Option exercise Acquire M No No 11.08 1,500 16.62K 80,289
4 Oct 21 Michael P. Dillon Stock Option Common Stock Option exercise Dispose M No No 11.08 1,500 16.62K 23,437
8 Sep 21 Michael P. Dillon Common Stock Sell Dispose S No Yes 27.67 200 5.53K 78,789
8 Sep 21 Michael P. Dillon Common Stock Sell Dispose S No Yes 27.4105 11,184 306.56K 78,989
8 Sep 21 Michael P. Dillon Common Stock Option exercise Acquire M No No 11.08 4,313 47.79K 90,173
8 Sep 21 Michael P. Dillon Common Stock Option exercise Acquire M No No 4.31 7,071 30.48K 85,860
8 Sep 21 Michael P. Dillon Stock Option Common Stock Option exercise Dispose M No No 11.08 4,313 47.79K 24,937

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

80.8% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 87 92 -5.4%
Opened positions 7 19 -63.2%
Closed positions 12 11 +9.1%
Increased positions 43 32 +34.4%
Reduced positions 18 22 -18.2%
13F shares
Current Prev Q Change
Total value 601.9M 836.89M -28.1%
Total shares 31.02M 30.86M +0.5%
Total puts 0 18.2K EXIT
Total calls 0 22.2K EXIT
Total put/call ratio 0.8
Largest owners
Shares Value Change
RTW Investments 3.27M $68.56M +32.4%
Canaan Partners X 2.66M $55.85M 0.0%
BLK Blackrock 2.6M $54.63M +85.0%
Boxer Capital 2.2M $46.24M 0.0%
Avidity Partners Management 2.07M $43.45M +40.6%
5AM Venture Management 1.8M $37.74M 0.0%
Biotechnology Value Fund L P 1.79M $37.38M -44.6%
FHI Federated Hermes 1.64M $34.36M +8.7%
BMY Bristol-Myers Squibb 1.63M $11.07M 0.0%
5AM Ventures IV 1.55M $25.35M 0.0%
Largest transactions
Shares Bought/sold Change
BVF 0 -2.61M EXIT
Biotechnology Value Fund L P 1.79M -1.44M -44.6%
BLK Blackrock 2.6M +1.2M +85.0%
RTW Investments 3.27M +800K +32.4%
Avidity Partners Management 2.07M +598K +40.6%
Ally Bridge 510.41K +480.41K +1601.4%
TROW T. Rowe Price 1.31M +409.71K +45.5%
AXAHF Axa 240.11K +240.11K NEW
Vanguard 1.07M +192.25K +21.9%
Marshall Wace North America 0 -167.57K EXIT

Financial report summary

  • Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies.
  • Clinical development of one of our product candidates, darovasertib, depends, in part, on data from Novartis’ ongoing Phase 1 clinical trial of darovasertib in patients with metastatic uveal melanoma. We have no control over the execution of Novartis’ trial.
  • As an organization, we have never completed a clinical trial, and may be unable to do so for any of our product candidates.
  • The successful development of targeted therapeutics, including therapeutics involving direct targeting of an oncogenic pathway and synthetic lethality therapeutics, including our portfolio of synthetic lethality small molecule inhibitors, as well as any related diagnostics, is highly uncertain.
  • Preclinical and clinical drug development is a lengthy and expensive process with an uncertain outcome. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of any product candidates, which could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our business, financial condition, results of operations and prospects. Furthermore, results of earlier studies and trials may not be predictive of future trial results.
  • Tissue-type agnostic basket trials are an emerging clinical approach, that may result in delays in clinical development, additional regulatory requirements and delays in, or the prevention of, our ability to obtain regulatory approval or commercialize our product candidates.
  • We may find it difficult to enroll patients in our clinical trials given the limited number of patients who have the diseases for which our product candidates are being developed. If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.
  • If we are unable to successfully develop molecular diagnostics for biomarkers that enable patient selection and/or that demonstrate drug-target interaction, or experience significant delays in doing so, we may not realize the full commercial potential of our product candidates.
  • The failure to obtain required regulatory approvals for any companion diagnostic tests that we may pursue may prevent or delay approval of our product candidates. Moreover, the commercial success of any of our product candidates may be tied to the regulatory approval, market acceptance and continued availability of a companion diagnostic.
  • We may be unable to obtain regulatory approval for our product candidates or any future product candidates. The denial or delay of such approval would prevent or delay commercialization of our product candidates and adversely impact our business, financial condition, operating results and prospects.
  • A breakthrough therapy designation by the FDA for our product candidates may not lead to a faster development or regulatory review or approval process, and it does not increase the likelihood that our product candidates will obtain marketing approval.
  • We expect to expand our development and regulatory capabilities and potentially implement sales and distribution capabilities, and as a result, we will need to increase the size of our organization, and we may experience difficulties in managing growth.
  • We currently have no sales organization. If we are unable to establish sales capabilities on our own or through third parties, we may not be able to market and sell any products effectively, if approved, or generate product revenue.
  • If we fail to attract and retain senior management and key scientific personnel, our business may be materially and adversely affected.
  • Our employees and independent contractors, including principal investigators, consultants, collaborators, service providers and other vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have an adverse effect on our results of operations.
  • We attempt to distribute our technology, biology, execution and financing risks across a range of therapeutic classes, disease states, programs and technologies. Due to the significant resources required for the development of our broad portfolio of programs, and depending on our ability to access capital, we must make certain risk assessments and prioritize development of certain product candidates. Moreover, we may expend our limited resources to pursue a particular product candidate and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.
  • The COVID-19 pandemic, or any other pandemic, epidemic or outbreak of an infectious disease may materially and adversely affect our business and operations, including the pace of enrollment in current or future clinical trials.
  • We or the third parties upon whom we depend may be adversely affected by earthquakes or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.
  • We rely on third parties to conduct certain of our preclinical studies and all of our clinical trials and intend to rely on third parties in the conduct of all of our future clinical trials. If these third parties do not successfully carry out their contractual duties, fail to comply with applicable regulatory requirements or meet expected deadlines, it may delay or prevent us from seeking or obtaining regulatory approval or commercializing our current or future product candidates.
  • We depend on third-party suppliers for key materials required for the production of our product candidates, and the loss of these third-party suppliers or their inability to supply us with adequate materials could harm our business.
  • If we fail to comply with our obligations under our license agreement with Novartis, we could lose license rights that are important to our business.
  • Our existing collaboration arrangements and any collaboration arrangements that we may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize our product candidates or diagnostics associated with such product candidates.
  • Even if our product candidates or any future product candidate obtains regulatory approval, they may fail to achieve the broad degree of physician and patient adoption and use necessary for commercial success.
  • The successful commercialization of any products will depend in part on the extent to which governmental authorities, private health insurers, managed care plans and other third-party payors provide coverage, adequate reimbursement levels and implement pricing policies favorable for any products. Failure to obtain or maintain coverage and adequate reimbursement for products, if approved, could limit our ability to market those products and decrease our ability to generate revenue.
  • If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of any products.
  • If we do not obtain patent term extension for patents covering our product candidates, our business may be materially harmed, and in any case, the terms of our patents may not be sufficient to effectively protect our product candidates and business.
  • Third-party claims of intellectual property infringement could require us to spend significant time and money and could prevent us from selling our products.
  • We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming, and unsuccessful. Further, our issued patents could be found invalid or unenforceable if challenged.
  • We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.
  • If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.
  • Intellectual property rights do not necessarily address all potential threats to our competitive advantage.
  • An active, liquid and orderly market for our common stock may not be maintained, and you may not be able to resell your common stock.
  • Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall.
  • If we engage in future acquisitions or strategic collaborations, it may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities and subject us to other risks.
  • We may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses.
  • Changes in patent law in the United States or in other countries could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.
  • Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
  • If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline.
  • If we are unable to maintain effective internal controls, our business, financial position, results of operations and prospects could be adversely affected.
  • We are an “emerging growth company,” and the reduced disclosure requirements applicable to emerging growth companies may make our common stock less attractive to investors.
  • If we sell shares of our common stock in future financings, stockholders may experience immediate dilution and, as a result, our stock price may decline.
  • Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.
  • Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management.
  • Our amended and restated certificate of incorporation provides for an exclusive forum in the Court of Chancery of the State of Delaware and in the U.S. federal district courts for certain disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.
Management Discussion
  • Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
  • We are a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Our approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations most likely to benefit.  Our small molecule drug discovery expertise includes discovery and development of small molecule inhibitors and protein degrader modalities. We are applying these capabilities to develop a robust pipeline in precision medicine oncology, with a research focus in synthetic lethality – which represents an emerging class of precision medicine targets.
  • Our most advanced synthetic lethality product candidate is IDE397, a clinical-stage methionine adenosyltransferase 2a, or MAT2A, inhibitor being developed for solid tumors with MTAP deletions.
Content analysis
H.S. senior Avg
New words: adenoid, aminotransminase, Anticancer, bilirubin, biopsy, Bioscience, chronic, cystic, fifty, FoRx, hosting, marker, myelosuppression, onstipation, pharmacokinetic, plasma, port, project, PWS, ready, Ribon, Riovant, threshold, thymic, transient, trunk, week, wine
Removed: attached, certification, County, exhibit, feasibility, Governor, Hata, irrespective, language, Mateo, Paul, pediatric, signature, Stone, Tesaro, undersigned, Yujiro